Evangeline R Jackson
Evangeline Jackson was awarded a B. Biomedical Science (Hons 1) in 2019. Evangeline is currently a PhD candidate in the Cancer Signalling Research Group at the University of Newcastle under the supervision of A/Prof Matthew Dun. Evangeline's project investigates the novel therapeutic, ONC201 for treatment of diffuse midline glioma (DMG). Using sophisticated methods in proteomics and molecular biochemistry, to inform mechanistic studies aimed at improving treatment response through combination treatment paradigms. Her preclinical work on the combination of ONC201 and the PI3K/Akt inhibitor, paxalisib, underpins the PNOC022 international clinical trial testing the combination therapy for DMG patients (NCT05009992).
Abstracts this author is presenting:
